Business Context and Reporting Period
This Form 8-K is a current report filed by OncoCyte Corporation (not Insight Molecular Diagnostics Inc.) on August 14, 2017. The filing serves to announce the company's financial results for the three and six months ended June 30, 2017. The registrant is an emerging growth company incorporated in California.
Key Financial Metrics
The filing text itself does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release attached as Exhibit 99.1, which is incorporated by reference but not reproduced in the body of this 8-K.
Material Changes
No specific material changes versus prior periods are detailed in the text of this filing. The document solely references the issuance of the press release containing the comparative financial results.
Guidance, Outlook, and Risks
- Forward-Looking Statements: The filing includes a standard disclaimer that statements containing words such as "may," "will," "believes," or "expects" are forward-looking and subject to risks.
- Risk Factors: Investors are directed to the "Risk Factors" section of the company's Form 10 for details on factors that could cause actual results to differ materially from anticipated results.
- Legal Status: The report and Exhibit 99.1 are deemed "furnished" rather than "filed" under Section 18 of the Exchange Act and are not subject to the liability of that section.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing Exhibit 99.1 (the press release dated August 14, 2017), as they are not listed in this summary document.
- Confirm the company name is OncoCyte Corporation, noting the discrepancy with the metadata field "Insight Molecular Diagnostics Inc."
- Review the "Risk Factors" in the company's Form 10 to understand the uncertainties surrounding the forward-looking statements mentioned in this filing.
- Check the company's status as an emerging growth company and its election regarding the extended transition period for accounting standards.